폐암 (NSCLC)

ADCBiologicstaleImmunome, Inc.Phase 1

IM-1617 (IM-1617)

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

AntibodystaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#항체#면역항체+2

AntibodystaleUniversity of ChicagoPhase 2

for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab (Investigator Choice Immunotherapy, Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab))

Non-Small Cell Lung Cancer; Metastatic Lung Cancer · Non-Small Cell Lung Cancer

AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab plus guadecitabine)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleInSightecPhase 3

Iptilimumab (Iptilimumab)

Brain Tumor; Non Small Cell Lung Cancer · Brain Tumor

#BrainTumor#Antibody#Phase3#항체#면역항체+3

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

KK-LC-1 TCR (KK-LC-1 TCR)

Kita-kyushu Lung Cancer Antigen 1, Human · Kita-kyushu Lung Cancer Antigen 1, Human

#Kita-kyushuLungCancerAntigen1Hum#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

AntibodystaleShanghai Pulmonary Hospital, Sh…Phase 2

LM-108+Sintilimab (LM-108+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2

AntibodystaleAline Fusco Fares, MDPhase 2

nivolumab (Opdivo, Low-dose nivolumab combined with platinum-based doublet chemotherapy)

Lung Cancer, Nonsmall Cell; Non-Small Cell Lung Cancer NSCLC · Lung Cancer, Nonsmall Cell

#LungCancerNonsmallCell#Antibody#Phase2#항체#면역항체+5

CGTBiologicstaleFred Hutchinson Cancer CenterPhase 2

MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Lung Non-Small Cell Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#CGT#Phase2#세포유전치료#CAR-T+3

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2

효능 ORR 40.3%임상시험 1상태 ACTIVE

CGTBiologicstaleUniversity of PennsylvaniaPhase 1

MOv19-BBz CAR T cells (MOv19-BBz CAR T cells)

Metastatic Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Non Small Cell Lung Cancer

#MetastaticNonSmallCellLungCancer#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#PD-L1#Antibody#Phase2#항체#면역항체+4

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

효능 ORR 6%임상시험 1상태 RECRUITING

#PD-L1#Antibody#Phase2#항체#면역항체+4

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

효능 ORR 6%임상시험 1상태 RECRUITING

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer